A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer: The VIOLETTA Trial
A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer Using Organ Based Tracking (OBT) Navigation: The VIOLETTA Trial
This study is to investigate the efficacy of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a prospective multi-centre trial in 5 hospitals in 4 countries to investigate the efficacy and complications of TMA as a minimally invasive focal therapy for PCa. Men aged ≥50 with PSA < 20ng/mL, 1-2 MRI lesions with maximal dimension ≤15mm and ISUP grade group 2-3 PCa will be recruited. Transperineal TMA of the prostate tumor(s) will be done with repeated ablations by a single microwave needle guided by MRI-Ultrasound fusion and OBT navigation. The primary outcome is any clinically significant PCa (csPCa) detected on biopsy of treated area(s) per patient at 12 months.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Peter Ka-Fung CHIU, PhD,MBChB
- Phone Number: 35052625
- Email: peterchiu@surgery.cuhk.edu.hk
Study Locations
-
-
-
Shatin, Hong Kong
- Recruiting
- Peter Ka-Fung CHIU
-
Contact:
- Peter Ka-Fung CHIU, PhD,MBChB
- Phone Number: 35052625
- Email: peterchiu@surgery.cuhk.edu.hk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
(i) Men aged ≥50 years old (ii) Life expectancy > 10 years upon recruitment (iii) Able to understand the trial and can provide informed and written consent, dated and signed before the enrollment and before any exam required by the trial (iv) Localized intermediate risk prostate cancer diagnosed on MRI-Ultrasound fusion targeted biopsy (v) Organ-confined prostate cancer on MRI (vi) PSA < 20 ng/mL (vii) 1-2 MRI visible lesion present with maximal tumor dimension ≤15mm, with targeted biopsy showing:
- ISUP grade group 2 or 3 PCa
- Systematic biopsies showing grade group 1-3 PCa just next to the MRI lesion is allowed
- Systematic biopsies showing grade group 1 PCa far away from the lesion is allowed
Exclusion criteria:
(i) Patients not fit for general or spinal anaesthesia (ii) Patients unfit for MRI exam or MR gadolinium contrast (e.g. estimated glomerular filtration rate (eGFR) of <50 ml/min) (iii) Patients with coagulopathy that cannot be corrected (iv) Patients on anticoagulants or antiplatelets that cannot be stopped (Low dose Aspirin, e.g. 80-100mg, is acceptable and no need to stop before or during TMA treatment) (v) Patients with previous treatment of prostate cancer (vi) Patients with prior pelvic radiotherapy for prostate cancer or other cancer (vii) Patients with maximal length of target lesion >15mm (viii) Patients with MRI lesion within 10mm from rectum or 10mm from sphincter on MRI (ix) Patients with >2 areas (MRI-visible or invisible) of prostate cancer (x) Patients with Gleason score 4+4 or any Gleason pattern 5 cancer (xi) Patients with systematic cores showing any Gleason 4 pattern PCa which are not adjacent to the target lesions (1 core of Gleason 3 pattern PCa on systematic cores in contralateral lobe is acceptable) (xii) Patients with definite extracapsular disease on imaging (prostate capsular contact without definite extra-capsular extension is acceptable) (xiii) Patients with bladder pathology including bladder stone or bladder cancer (xiv) Patients with known urethral stricture
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Targeted Microwave Ablation (TMA)
Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation |
Targeted microwave ablation (TMA) is a novel treatment developed for focal treatment of prostate cancer, and it is applied with precise navigation guidance under the organ-based tracking (OBT) mechanism. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The oncological control of prostate cancer
Time Frame: At 12 months after treatment
|
Any clinically significant PCa (csPCa) detected on biopsy of treated area(s) per patient at 12 months after treatment, defined by: • ISUP grade group 2 or above PCa |
At 12 months after treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinically significant cancer detection on biopsy of each ablated MRI visible lesion
Time Frame: At 12 months after treatment
|
Per-lesion analysis of csPCa detected on biopsy of any ablated areas at 12 months |
At 12 months after treatment
|
|
Cancer detection on biopsy of each ablated MRI invisible lesion
Time Frame: At 12 months after treatment
|
Per-lesion analysis of any cancer detected on biopsy of any ablated areas at 12 months |
At 12 months after treatment
|
|
Out-of-field recurrence: Any cancer outside treated area on systematic biopsy
Time Frame: At 12 months after treatment
|
Out-of-field recurrence: Any cancer outside treated area on systematic biopsy |
At 12 months after treatment
|
|
Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Time Frame: At 3 Month, 6 Month and 12 Month
|
Complications of treatment using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
At 3 Month, 6 Month and 12 Month
|
|
PSA change
Time Frame: At baseline, 3 Month and 6 Month and 12 Month
|
PSA change after treatment |
At baseline, 3 Month and 6 Month and 12 Month
|
|
Urinary Symptoms after treatment
Time Frame: At baseline, 3 Month, 6 Month and 12 Month
|
Urinary symptoms measured by IPSS score, score ranging from 0-35 (the higher the worse) |
At baseline, 3 Month, 6 Month and 12 Month
|
|
Sexual side effects after treatment
Time Frame: At baseline, 3 Month, 6 Month and 12 Month
|
Sexual side effects, up to 1 year, measured by IIEF-5 score (ranging from 1-25), the lower the worse |
At baseline, 3 Month, 6 Month and 12 Month
|
|
Continence side effects after treatment
Time Frame: At baseline, 3 Month, 6 Month and 12 Month
|
Continence side effects, up to 1 year, measured by EPIC-26 questionnaire, the lower score the worse |
At baseline, 3 Month, 6 Month and 12 Month
|
|
Common Terminology Criteria for Adverse Events (CTCAE) rectal toxicity
Time Frame: At baseline, 3 Month, 6 Month and 12 Month
|
Rectal toxicity of treatment using Common Terminology Criteria for Adverse Events |
At baseline, 3 Month, 6 Month and 12 Month
|
|
Quality of life measured by ED-5Q-5Lquestionnaire
Time Frame: At baseline, 3 Month, 6 Month and 12 Month
|
Quality of life measured by ED-5Q-5L questionnaire, the higher the score the better in quality of life |
At baseline, 3 Month, 6 Month and 12 Month
|
|
Quality of life in patients with prostate cancer measured by EPIC-26
Time Frame: At baseline, 3 Month, 6 Month and 12 Month
|
Quality of life in patients with prostate cancer measured by EPIC-26 range 0-100, the higher score the better the quality of life |
At baseline, 3 Month, 6 Month and 12 Month
|
|
Quality of life measured by QLQ-C30
Time Frame: At baseline, 3 Month, 6 Month and 12 Month
|
Quality of life measured by QLQ-C30, score 0-100, the higher the score the better in quality of life |
At baseline, 3 Month, 6 Month and 12 Month
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Peter Ka-Fung CHIU, PhD,MBChB, Chinese University of Hong Kong
Publications and helpful links
General Publications
- Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2020 Jan;77(1):38-52. doi: 10.1016/j.eururo.2019.08.005. Epub 2019 Sep 5.
- Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 2019 Sep;76(3):340-351. doi: 10.1016/j.eururo.2019.02.033. Epub 2019 Mar 18.
- Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG, Dickinson L, Allen C, Punwani S, Jameson C, Freeman A, McCartan N, Montorsi F, Briganti A, Ahmed HU, Emberton M, Moore CM. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int. 2019 Sep;124(3):431-440. doi: 10.1111/bju.14710. Epub 2019 Mar 18.
- Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr;10(2):63-89. doi: 10.14740/wjon1191. Epub 2019 Apr 20.
- Barry Delongchamps N, Schull A, Anract J, Abecassis JP, Zerbib M, Sibony M, Jilet L, Abdoul H, Goffin V, Peyromaure M. Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial. PLoS One. 2021 Jul 14;16(7):e0252040. doi: 10.1371/journal.pone.0252040. eCollection 2021.
- Durand M, Barret E, Galiano M, Rozet F, Sanchez-Salas R, Ahallal Y, Macek P, Gaya JM, Cerruti J, Devilliers H, Loeffler J, Amiel J, Vallancien G, Cathelineau X. Focal cryoablation: a treatment option for unilateral low-risk prostate cancer. BJU Int. 2014 Jan;113(1):56-64. doi: 10.1111/bju.12370. Epub 2013 Oct 31.
- Shah TT, Peters M, Eldred-Evans D, Miah S, Yap T, Faure-Walker NA, Hosking-Jervis F, Thomas B, Dudderidge T, Hindley RG, McCracken S, Greene D, Nigam R, Valerio M, Minhas S, Winkler M, Arya M, Ahmed HU. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol. 2019 Jul;76(1):98-105. doi: 10.1016/j.eururo.2018.12.030. Epub 2019 Jan 9.
- Chiu PK, Chan CH, Yee CH, Lau SY, Teoh JY, Wong HF, Lo KL, Yuen TY, Hung HY, Cho CC, Ng CF. Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):736-742. doi: 10.1038/s41391-022-00577-8. Epub 2022 Jul 14.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CRE-2023.079
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.